Biothera Inc.

Hibercell, Inc.

Nandita Bose

Keith B Gorden

Michael E Danielson

Mary A Antonysamy

William J Grossman

Anissa S H Chan

Richard M Walsh

Jeremy Graff

Kyle S Michel

Steven M Leonardo

Mariana I Nelson

Nadine Ottoson

Xiaohong Qiu

Peter Maimonis

Ross Fulton

Takashi Kangas

Kathryn A Fraser

Adria Bykowski Jonas

John P Vasilakos

Richard Huhn

Anissa Sh Chan

Mark Uhlik

Jamie Lowe

Ben Harrison

Steven Leonardo

This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

Methods for identifying beta-glucan binding to immune cells

This disclosure provides, in one aspect, dosing strategies for soluble &#x3b2;-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble &#x3b2;-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

Beta glucan immunopharmacodynamics

This disclosure describes, in one aspect, a method for identifying &#x3b2;-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble &#x3b2;-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble &#x3b2;-glucan to bind to the immune cells, and detecting soluble &#x3b2;-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of &#x3b2;-glucan, and co-administering to the subject a soluble &#x3b2;-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

The invention generally relates to soluble beta-glucan compositions and method of using such compositions. In one aspect, an adjuvant for a pharmaceutical composition is described which includes a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen. In another aspect, compositions that generally include an antigen component, a soluble beta-glucan component, and a TLR agonist component and a method that generally includes administering to a subject a composition that comprises a soluble beta-glucan and a TLR agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen, are described.

Compositions including beta-glucans and method of use

This disclosure relates to the combination of soluble &#x3b2;-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble &#x3b2;-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

&#x3b2;-glucan methods and compositions that affect the tumor microenvironment

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to &#x3b2;-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-&#x3b2;-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-&#x3b2;-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-&#x3b2;-glucan antibody.

Beta-glucan assay methods

The present invention relates to the combination of soluble &#x3b2;-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble &#x3b2;-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

This disclosure describes, in one aspect, a composition that includes a &#x3b2;-glucan component and an antibody component that specifically binds to the &#x3b2;-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to &#x3b2;-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of &#x3b2;-glucan and administering to the subject a composition that comprises a &#x3b2;-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.

Compositions and methods for beta-glucan immunotherapy

Described herein are compositions that include isolated opsonized soluble &#x3b2;-glucan, methods of making those compositions and methods of using those compositions.

Opsonized &#x3b2;-glucan preparations and methods

Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.

Growing community of inventors

Plymouth, MN, United States of America

Nandita Bose